Consultation: actions from September 2023 CRG meeting
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their September 2023 meeting. Actions in this consultation include:
- Tadalafil 5mg once daily – remove from DNP list and assign GREEN RAG status
- Herbal treatments – DNP listing amended to “herbal treatments and other natural products”, in line with NHS England guidance
- Cipaglucosidase alfa – add to formulary as RED
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
The consultation will run for six weeks and closes at 5pm on Friday 27th October 2023. To take part, visit the consultations page.
Formulary and RAG updates – August 2023
Following approval by CRG, the July meetings of GMMMG and the Greater Manchester ICS Clinical Effectiveness and Governance Committee, the following updates have been made to GMMMG guidelines, formulary, and RAG list:
- Tezepelmuab for treating severe asthma added to formulary as RED
- Fosofomycin for uncomplicated UTI updated to GREEN RAG status
- Greater Manchester Hypertension Medication pathway published, alongside supporting information and a medication table
- Greater Manchester Antimicrobial guidelines updated
- Ustekinumab dose-escalation in Crohn’s and ulcerative colitis – statement updated
The formulary has also been updated to reflect relevant safety alerts and NICE guidelines. For full details, see the GMMMG decision summary for August 2023, or the formulary change log available on the formulary page.
Formulary update – CGM
Following approval by the GM Executive, the following updates have been made to GMMMG guidelines, formulary, and RAG list:
- FreeStyle Libre 2 and Dexcom ONE added to formulary.
For full details, see the formulary change log available on the formulary page.
Consultation: steroid eye drop information for primary care prescribers
Following development by Manchester Royal Eye Hospital we now seek comments on the draft document: ‘Prescribing Information for Primary Care: Steroid Eye Drops for Ophthalmic Indications’.
The consultation will run for 6 weeks; please visit the consultations page to take part. The consultation will run until 5pm on Wednesday 27th September 2023.
Please note: the RAG status of the steroid eyedrops is currently undergoing a separate consultation, with a proposed change from RED to GREEN (following specialist initiation). Please see the proposed actions from the August 2023 meeting of the Clinical Reference Group for more details.
Consultation: actions from August 2023 CRG meeting
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their August 2023 meeting. Actions in this consultation include:
- Sodium chloride 5% eye drops – RED
- Bempedoic acid – comments sought regarding a change to GREEN
- Steroid eye drops (betamethasone 0.1%, dexamethasone 0.1%, prednisolone 0.03%, 0.1%, 0.5% & 1%, fluorometholone 0.1%) – GREEN (specialist initiation)
- Rimegepant for preventing migraine – GREEN (specialist initiation) OR GREEN (specialist advice)
- Semaglutide for overweight and obesity in young people aged 12-17 years – Do Not Prescribe.
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
The consultation will run for six weeks and closes at 5pm on Friday 22nd September 2023. To take part, visit the consultations page.
Formulary and RAG updates – July 2023
Following approval by CRG, the July meetings of GMMMG and the Greater Manchester ICS Clinical Effectiveness and Governance Committee, and review by the GM Executive, the following updates have been made to GMMMG guidelines, formulary, and RAG list:
- Finerenone for CKD in type 2 diabetes added as GREEN (specialist advice)
- Semaglutide for overweight and obesity added as RED
- Orodispersible morphine added as GREEN and GREY, only for use when specified criteria are met
- Eptinezumab for preventing migraine added as RED
- Hydrocortisone modified release capsules (Efmody) added as GREEN (following specialist initiation), only for patients not well controlled on standard release preparations and where specified criteria are met
- Dapagliflozin for CKD in children added to paediatric RAG list as RED
- Chloral hydrate and cloral betaine added to the RAG list only as RED
- Asfotase alfa added to the RAG list only as RED
The formulary has also been updated to reflect relevant safety alerts and NICE guidelines. For full details, see the GMMMG decision summary for July 2023, or the formulary change log available on the formulary page.
Consultation: updated HCD inflammatory bowel disease pathway
Following development by a clinical working group and review by CRG, we now seek comments on the draft update of the GMMMG High Cost Drugs Inflammatory Bowel Disease Pathway.
The consultation will run for 6 weeks, closing at 5pm on 30th August. To take part, please visit the consultations page.
Consultation: Safe management of medicines within GP practices
Following development by Wigan Borough locality and adaptation by the GM Medicines Safety Group, we now seek comments on the draft document: ‘Safe Management of Medicines within GP Practices, An Example of Good Practice’.
The consultation will run for 6 weeks, closing at 5pm on 30th August. To take part, please visit the consultations page.
Consultation: omalizumab for chronic inducible urticaria
The Greater Manchester Clinical Reference Group reviewed a request to add omalizumab to formulary for the unlicensed indications of severe chronic inducible urticarias (solar urticaria, cold and heat urticaria, symptomatic dermographism, delayed pressure urticaria and cholinergic urticaria). We now seek comments on this draft
The consultation will run for 6 weeks, closing at 5pm on 29th August. To take part, please visit the consultations page.
Consultation: actions from July CRG meeting
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their July 2023 meeting. Actions in this consultation include:
- Bulevirtide for chronic hepatitis D – add to formulary as RED
- Esketamine for major depressive disorder in adults at imminent risk of suicide – update existing DNP listing to include this indication
- Dapagliflozin for chronic heart failure with preserved or mildly reduced ejection fraction – add to formulary as GREEN (following specialist advice)
- Upadacitinib for Crohn’s disease – add to formulary as RED
- Deucravactinib for plaque psoriasis – add to formulary as RED
- Emollient bath additives – update DNP listing to include reference to new NICE ‘do not do’ recommendation
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
The consultation will run for six weeks and closes at 5pm on Tuesday 29th August 2023. To take part, visit the consultations page.